Microbicide Sponsors Propose AE Registry To Decrease FDA's OTC Concerns
Executive Summary
Registries that track adverse events resulting from microbicide use should ease FDA concerns about making the drugs available over the counter, ReProtect Medical Director Thomas Moench, MD, suggested to FDA's Rx-to-OTC switch public hearing June 29.